Catherine Shaffer

When patients with solid tumors had the same findings using liquid- and tissue-based tests from Foundation Medicine, patients had better outcomes on molecular tumor board-guided therapy.

The firm is using single-cell, multiomics analysis to probe tumor samples from very long-term cancer survivors for keys to defeating the disease.

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

Several new studies appear to confirm the test's potential to prevent overtreatment of melanoma patients while identifying those at high risk.

Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.

Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.

The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.

The firm is building a case for clinical utility of its gene expression test for cancer of unknown primary following a successful validation study.

In a Nature Medicine paper, WGS yielded a clinical benefit for 24 percent of pediatric cancer patients, and directly changed clinical management for 7 percent.